JP2017502668A5 - - Google Patents

Download PDF

Info

Publication number
JP2017502668A5
JP2017502668A5 JP2016543143A JP2016543143A JP2017502668A5 JP 2017502668 A5 JP2017502668 A5 JP 2017502668A5 JP 2016543143 A JP2016543143 A JP 2016543143A JP 2016543143 A JP2016543143 A JP 2016543143A JP 2017502668 A5 JP2017502668 A5 JP 2017502668A5
Authority
JP
Japan
Prior art keywords
nucleic acid
nucleotides
length
oligonucleotide
hao1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016543143A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017502668A (ja
JP6886818B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/072410 external-priority patent/WO2015100436A1/en
Publication of JP2017502668A publication Critical patent/JP2017502668A/ja
Publication of JP2017502668A5 publication Critical patent/JP2017502668A5/ja
Application granted granted Critical
Publication of JP6886818B2 publication Critical patent/JP6886818B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016543143A 2013-12-27 2014-12-26 二本鎖rnaによるグリコール酸オキシダーゼ(hao1)の特異的阻害に関する方法および組成物 Active JP6886818B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361921181P 2013-12-27 2013-12-27
US61/921,181 2013-12-27
US201461937838P 2014-02-10 2014-02-10
US61/937,838 2014-02-10
PCT/US2014/072410 WO2015100436A1 (en) 2013-12-27 2014-12-26 Methods and compositions for the specific inhibition of glycolate oxidase (hao1) by double-stranded rna

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019202937A Division JP7109416B2 (ja) 2013-12-27 2019-11-08 二本鎖rnaによるグリコール酸オキシダーゼ(hao1)の特異的阻害に関する方法および組成物

Publications (3)

Publication Number Publication Date
JP2017502668A JP2017502668A (ja) 2017-01-26
JP2017502668A5 true JP2017502668A5 (enExample) 2018-02-08
JP6886818B2 JP6886818B2 (ja) 2021-06-16

Family

ID=53479713

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016543143A Active JP6886818B2 (ja) 2013-12-27 2014-12-26 二本鎖rnaによるグリコール酸オキシダーゼ(hao1)の特異的阻害に関する方法および組成物
JP2019202937A Active JP7109416B2 (ja) 2013-12-27 2019-11-08 二本鎖rnaによるグリコール酸オキシダーゼ(hao1)の特異的阻害に関する方法および組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019202937A Active JP7109416B2 (ja) 2013-12-27 2019-11-08 二本鎖rnaによるグリコール酸オキシダーゼ(hao1)の特異的阻害に関する方法および組成物

Country Status (21)

Country Link
US (7) US9701966B2 (enExample)
EP (3) EP3892727A1 (enExample)
JP (2) JP6886818B2 (enExample)
AU (2) AU2014369850B2 (enExample)
CA (1) CA2935220A1 (enExample)
CY (2) CY1124203T1 (enExample)
DK (2) DK3087184T3 (enExample)
ES (2) ES2875558T3 (enExample)
FI (1) FIC20210025I1 (enExample)
FR (1) FR21C1044I2 (enExample)
HR (1) HRP20210612T1 (enExample)
HU (2) HUE055470T2 (enExample)
LT (2) LT3581654T (enExample)
LU (1) LUC00218I2 (enExample)
NO (1) NO2021038I1 (enExample)
PL (1) PL3581654T3 (enExample)
PT (1) PT3581654T (enExample)
RS (1) RS61892B1 (enExample)
SI (1) SI3581654T1 (enExample)
SM (1) SMT202100325T1 (enExample)
WO (1) WO2015100436A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9879266B2 (en) 2002-11-14 2018-01-30 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
US9228186B2 (en) 2002-11-14 2016-01-05 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
RS61892B1 (sr) 2013-12-27 2021-06-30 Dicerna Pharmaceuticals Inc Postupci i kompozicije za specifičnu inhibiciju glikolat oksidaze (hao1) pomoću dvolančane rnk
TWI755351B (zh) * 2014-10-10 2022-02-21 美商艾爾妮蘭製藥公司 用於抑制hao1(羥酸氧化酶1(乙醇酸鹽氧化酶))基因表現的組合物及方法
WO2016205323A1 (en) * 2015-06-18 2016-12-22 Alnylam Pharmaceuticals, Inc. Polynucleotde agents targeting hydroxyacid oxidase (glycolate oxidase, hao1) and methods of use thereof
CA3036620A1 (en) * 2016-10-05 2018-04-12 Syngenta Participations Ag Methods of preserving the biological activity of ribonucleic acids
WO2018102397A1 (en) 2016-11-29 2018-06-07 PureTech Health LLC Exosomes for delivery of therapeutic agents
AU2018301829B2 (en) 2017-07-13 2024-08-01 Alnylam Pharmaceuticals, Inc. Methods for inhibition of HAO1 (hydroxyacid oxidase 1 (glycolate oxidase) gene expression
AU2019313348A1 (en) * 2018-07-31 2021-03-04 Intellia Therapeutics, Inc. Compositions and methods for hydroxyacid oxidase 1 (HAO1) gene editing for treating primary hyperoxaluria type 1 (PH1)
EP3898661A1 (en) * 2018-12-21 2021-10-27 Precision BioSciences, Inc. Genetic modification of the hydroxyacid oxidase 1 gene for treatment of primary hyperoxaluria
WO2021086874A1 (en) 2019-11-01 2021-05-06 GyanRx Sciences, Inc. Heterocyclic carboxylate compounds as glycolate oxidase inhibitors
EP4153752A4 (en) * 2020-05-22 2025-10-01 Harvard College INTERFERON-INDUCING OLIGONUCLEOTIDE DUPLEXES AND METHODS OF USE
WO2022104062A1 (en) 2020-11-12 2022-05-19 Precision Biosciences, Inc. Engineered meganucleases having specificity for recognition sequences in the dystrophin gene
EP4043018A1 (en) 2021-02-10 2022-08-17 Charité - Universitätsmedizin Berlin Composition and method for reducing oxalate levels in patients receiving maintenance dialysis
CA3222159A1 (en) * 2021-06-04 2022-12-08 Arbor Biotechnologies, Inc. Gene editing systems comprising an rna guide targeting hydroxyacid oxidase 1 (hao1) and uses thereof
JP2024528659A (ja) * 2021-07-19 2024-07-30 アルナイラム ファーマシューティカルズ, インコーポレイテッド 非原発性高シュウ酸尿症疾患または障害を有するまたは発症するリスクがある対象を治療するための方法および組成物

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US513207A (en) 1894-01-23 Rail-brake
US5432272A (en) 1990-10-09 1995-07-11 Benner; Steven A. Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
JP3257675B2 (ja) 1990-10-12 2002-02-18 マックス−プランク−ゲゼルシャフト ツール フェルデルング デル ビッセンシャフテン エー.ファウ. 修飾リボザイム
US5652094A (en) 1992-01-31 1997-07-29 University Of Montreal Nucleozymes
US6469158B1 (en) 1992-05-14 2002-10-22 Ribozyme Pharmaceuticals, Incorporated Synthesis, deprotection, analysis and purification of RNA and ribozymes
US5977343A (en) 1992-05-14 1999-11-02 Ribozyme Pharmaceuticals, Inc. Synthesis, deprotection, analysis and purification of RNA and ribozymes
US5804683A (en) 1992-05-14 1998-09-08 Ribozyme Pharmaceuticals, Inc. Deprotection of RNA with alkylamine
JPH09502092A (ja) 1993-09-02 1997-03-04 リボザイム・ファーマシューティカルズ・インコーポレイテッド 非ヌクレオチドを含有する酵素性核酸
US5889136A (en) 1995-06-09 1999-03-30 The Regents Of The University Of Colorado Orthoester protecting groups in RNA synthesis
US5998203A (en) 1996-04-16 1999-12-07 Ribozyme Pharmaceuticals, Inc. Enzymatic nucleic acids containing 5'-and/or 3'-cap structures
US6218108B1 (en) 1997-05-16 2001-04-17 Research Corporation Technologies, Inc. Nucleoside analogs with polycyclic aromatic groups attached, methods of synthesis and uses therefor
US6248878B1 (en) 1996-12-24 2001-06-19 Ribozyme Pharmaceuticals, Inc. Nucleoside analogs
US6111086A (en) 1998-02-27 2000-08-29 Scaringe; Stephen A. Orthoester protecting groups
US7678897B2 (en) * 2002-02-20 2010-03-16 Sirna Therapeutics, Inc. RNA interference mediated inhibition of platelet-derived endothelial cell growth factor (ECGF1) gene expression using short interfering nucleic acid (siNA)
US8090542B2 (en) 2002-11-14 2012-01-03 Dharmacon Inc. Functional and hyperfunctional siRNA
WO2006006948A2 (en) 2002-11-14 2006-01-19 Dharmacon, Inc. METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
US9879266B2 (en) * 2002-11-14 2018-01-30 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
US20070265220A1 (en) 2004-03-15 2007-11-15 City Of Hope Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
US8084599B2 (en) 2004-03-15 2011-12-27 City Of Hope Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
AU2005248147A1 (en) 2004-05-11 2005-12-08 Alphagen Co., Ltd. Polynucleotides for causing RNA interference and method for inhibiting gene expression using the same
US20080213891A1 (en) 2004-07-21 2008-09-04 Alnylam Pharmaceuticals, Inc. RNAi Agents Comprising Universal Nucleobases
WO2007030167A1 (en) 2005-09-02 2007-03-15 Nastech Pharmaceutical Company Inc. Modification of double-stranded ribonucleic acid molecules
US8178503B2 (en) * 2006-03-03 2012-05-15 International Business Machines Corporation Ribonucleic acid interference molecules and binding sites derived by analyzing intergenic and intronic regions of genomes
JP4644619B2 (ja) 2006-03-27 2011-03-02 富士通株式会社 基地局装置、端末および帯域制御方法
DE102007021853A1 (de) 2007-05-10 2008-11-13 Norma Germany Gmbh Steckkupplung und Stutzen für eine Steckkupplung
US20110288147A1 (en) 2008-09-22 2011-11-24 Bob Dale Brown Compositions and methods for the specific inhibition of gene expression by DSRNA containing a tetraloop
CN101752443B (zh) 2008-12-08 2012-06-20 鸿富锦精密工业(深圳)有限公司 光伏电池
CN102325534B (zh) 2008-12-18 2016-02-17 戴瑟纳制药公司 延长的dicer酶底物和特异性抑制基因表达的方法
US20100249214A1 (en) 2009-02-11 2010-09-30 Dicerna Pharmaceuticals Multiplex dicer substrate rna interference molecules having joining sequences
EP2756845B1 (en) * 2009-04-03 2017-03-15 Dicerna Pharmaceuticals, Inc. Methods and compositions for the specific inhibition of KRAS by asymmetric double-stranded RNA
US8632982B2 (en) * 2009-05-21 2014-01-21 Institute For Systems Biology Biomarkers for liver injury
WO2013075035A1 (en) 2011-11-18 2013-05-23 Alnylam Pharmaceuticals Rnai agents, compositions and methods of use thereof for treating transthyretin (ttr) associated diseases
US9133461B2 (en) * 2012-04-10 2015-09-15 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of the ALAS1 gene
RS61892B1 (sr) 2013-12-27 2021-06-30 Dicerna Pharmaceuticals Inc Postupci i kompozicije za specifičnu inhibiciju glikolat oksidaze (hao1) pomoću dvolančane rnk
TWI755351B (zh) * 2014-10-10 2022-02-21 美商艾爾妮蘭製藥公司 用於抑制hao1(羥酸氧化酶1(乙醇酸鹽氧化酶))基因表現的組合物及方法

Similar Documents

Publication Publication Date Title
JP2017502668A5 (enExample)
JP2016528887A5 (enExample)
JP2015133993A5 (enExample)
JP2016526529A5 (enExample)
IL262667A (en) Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
IL264555B (en) Specific primers for nucleic acid amplification
JP2010524500A5 (enExample)
WO2015196128A3 (en) Alternative nucleic acid molecules and uses thereof
WO2015196130A3 (en) Alternative nucleic acid molecules and uses thereof
EP2791160A4 (en) NUCLEOSIDE, NUCLEOTIDE, AND MODIFIED NUCLEIC ACID COMPOSITIONS
ZA201701845B (en) Galnac phosphoramidites, nucleic acid conjugates thereof and their use
LT3041854T (lt) Nukleorūgščių specifinės vietos žymėjimo fermentais in vitro būdas, įvedant nenatūralius nukleotidus
SI3294325T1 (sl) Krepitev učinka car-izdelanih t celic s cepljenjem z nukleinsko kislino
MX2016007541A (es) Moléculas modificadas de ácido nucleico y usos de las mismas.
PT3118311T (pt) Ácido nucleico anti-sentido
HUE043054T2 (hu) Szubsztituált nukleozidok, nukleotidok és ezek analógjai
EP3237613A4 (en) Visualizing modified nucleotides and nucleic acid interactions in single cells
DK3294756T3 (da) Retroviral partikel, omfattende mindst to forskellige indkapslede, ikke-virale RNA'er
PT3632202T (pt) Locais genéticos associados a fertilidade acrescida em milho
HUE044390T2 (hu) Eljárás javított alakíthatósággal és szívósággal rendelkezõ nagyszilárdságú acéllemez gyártására, valamint az így nyert lemez
WO2016106387A3 (en) Nucleic acid aptamers to treat histone-induced disease states
EP3418289A4 (en) ARTIFICIAL NUCLEOSIDE AND ARTIFICIAL NUCLEOTIDE AND ARTIFICIAL OLIGONUCLEOTIDE
JP2016108250A5 (enExample)
RU2015154352A (ru) Генетическая конструкция для экспрессии генов в клетках насекомого polypedilum vanderplanki
JP2012024594A5 (ja) 払拭具及び払拭方法